Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

4 trials in Phase 3/4

Results Transparency

62%

8 of 13 completed trials have results

Key Signals

1 recruiting8 with results

Enrollment Performance

Analytics

Phase 2

6(46.2%)

Phase 3

4(30.8%)

Early Phase 1

1(7.7%)

Phase 1

1(7.7%)

N/A

1(7.7%)

13Total

Phase 2(6)

Phase 3(4)

Early Phase 1(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT03863145Early Phase 1Recruiting

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Role: lead

NCT03287219Phase 2Completed

Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX

Role: lead

NCT03099785Phase 2Completed

Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Role: lead

NCT03447821Phase 2Completed

Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

Role: lead

NCT00679380Phase 3Completed

(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Role: collaborator

NCT01100112Phase 3Completed

(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

Role: collaborator

NCT01520324Phase 2Completed

Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy

Role: lead

NCT02295774Phase 2Completed

Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA

Role: lead

NCT01142089Phase 3Completed

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

Role: lead

NCT02969252Phase 1Completed

Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers

Role: lead

NCT01694966Phase 3Completed

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Role: lead

NCT02654418Not ApplicableCompleted

Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm

Role: lead

NCT01520337Completed

Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy

Role: lead

NCT00867438Phase 2Completed

Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy

Role: lead

All 14 trials loaded